Predictors of response to pegylated interferon treatment in HBeAg-negative patients with chronic hepatitis B


Creative Commons License

GÜÇLÜ E., Tuna N., Karabay O., Akhan S., Bodur H., Ceylan B., ...Daha Fazla

JOURNAL OF INFECTION IN DEVELOPING COUNTRIES, cilt.8, sa.12, ss.1601-1608, 2014 (SCI-Expanded) identifier identifier identifier

Özet

Introduction: Although pegylated interferons (pegIFNs) alpha-2a and alpha-2b have been used in chronic hepatitis B (CHB) treatment for many years, there are few studies concerning predictors of sustained virologic response (SVR) to pegIFN therapy. In this study, we aimed to investigate the predictors of response to pegIFN treatment in cases with HBeAg-negative CHB infection.